Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Techne (TECH) EBIT Margin (2016 - 2025)

Bio-Techne has reported EBIT Margin over the past 17 years, most recently at 18.41% for Q4 2025.

  • Quarterly results put EBIT Margin at 18.41% for Q4 2025, up 244.0% from a year ago — trailing twelve months through Dec 2025 was 9.62% (down 712.0% YoY), and the annual figure for FY2025 was 8.38%, down 945.0%.
  • EBIT Margin for Q4 2025 was 18.41% at Bio-Techne, up from 16.63% in the prior quarter.
  • Over the last five years, EBIT Margin for TECH hit a ceiling of 2815.85% in Q3 2022 and a floor of 7.53% in Q2 2025.
  • Median EBIT Margin over the past 5 years was 22.62% (2021), compared with a mean of 160.08%.
  • Biggest five-year swings in EBIT Margin: surged 279132bps in 2022 and later crashed -279568bps in 2023.
  • Bio-Techne's EBIT Margin stood at 23.15% in 2021, then rose by 8bps to 25.0% in 2022, then crashed by -44bps to 13.94% in 2023, then increased by 15bps to 15.96% in 2024, then rose by 15bps to 18.41% in 2025.
  • The last three reported values for EBIT Margin were 18.41% (Q4 2025), 16.63% (Q3 2025), and 7.53% (Q2 2025) per Business Quant data.